Form 4: Phio Pharmaceuticals Director Robert Ferrara Increases Stake with Common Stock Purchase
Insider Transaction Report
Phio Pharmaceuticals Corp. Director Robert L. Ferrara has acquired 2,500 shares of common stock at $2.4199 per share, increasing his total beneficial ownership to 15,666 shares.
Summary
- Robert L. Ferrara, a Director of Phio Pharmaceuticals Corp. (PHIO), purchased 2,500 shares of the company's common stock.
- The transaction occurred on June 10, 2025, at a price of $2.4199 per share.
- Following this purchase, Mr. Ferrara's direct beneficial ownership in Phio Pharmaceuticals Corp. stands at 15,666 shares.
- The reported beneficial ownership includes shares of common stock underlying unvested restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is positive as a director's purchase of company stock typically indicates confidence in the company's future performance and valuation.
Positives
- The purchase of common stock by a director signals confidence in the company's future prospects and valuation.
- An increase in insider ownership aligns the interests of management with those of shareholders.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
Insider buying, such as this transaction by a director, is often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This can potentially boost investor confidence in Phio Pharmaceuticals within the biotechnology or pharmaceutical industry.
Stakeholder Impact
- Shareholders may view this insider purchase as a positive indicator of management's confidence in the company, potentially leading to increased investor interest and positive sentiment towards the stock.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date of common stock acquisition by Robert L. Ferrara. |
| 06/11/2025 | Date the Form 4 filing was signed by Robert L. Ferrara. |
Keywords
Phio Pharmaceuticals, PHIO, insider trading, stock purchase, director, common stock, Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.